Mayer on the Optimization of SERDs in ER+ Breast Cancer

Season 5 Episode 24  ·  Jul 15, 2021, 06:46 PM
Headliner
Share
Subscribe

Dr. Mayer discusses the mechanism of action of SERDs in ER-positive breast cancer, highlighted data from the AMEERA-1 trial with amcenestrant and palbociclib, and details future research efforts with SERDs.

Share
Subscribe
Next
Jabbour on Tailoring Treatment With TKIs in CML and Ph+ ALL
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air